Compare CSX Corporation (CSX) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs Novo Nordisk A/S — how do they compare? CSX Corporation trades at $50.1 (market cap $92.55B), while Novo Nordisk A/S trades at $45.94 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 2.2× CSX Corporation's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| CSX | NVO | |
|---|---|---|
Market Cap | $92.55B | $207.85B |
Sector | Industrials | Health |
52-Week High | $53.21 | $63.98 |
52-Week Low | $32.05 | $35.29 |
Enterprise Value | $110.52B | $222.55B |
Dividend Yield | 1.12% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $50.12, down 0.3% on the day, with a neutral technical signal. Recent Q2 2026 earnings beat estimates with EPS of $0.54 versus $0.518 expected, driven by 10% revenue growth and margin expansion. The stock's valuation ratios, including a P/E of 29.05 and P/S of 6.41, reflect a premium pricing relative to historical levels. Analyst consensus is bullish with a $52.57 price target, supported by 58.69% buy ratings.
The outlook for CSX is positive, with projected 2026 revenue growth and improved cash flow. Key opportunities include strong intermodal demand and operational efficiency gains. Risks involve competitive pressures, fuel cost volatility, and potential economic slowdowns affecting freight volumes. The stock's current level offers a moderate upside to the consensus target, balanced by elevated valuation multiples.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
